Schwab Charles Investment Management Inc. boosted its stake in Natera Inc (NASDAQ:NTRA) by 11.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 172,518 shares of the medical research company’s stock after acquiring an additional 18,051 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.32% of Natera worth $1,600,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Trexquant Investment LP purchased a new position in Natera in the 1st quarter worth approximately $119,000. MetLife Investment Advisors LLC purchased a new position in Natera in the 4th quarter worth approximately $124,000. Jefferies Group LLC purchased a new position in Natera in the 4th quarter worth approximately $130,000. Swiss National Bank boosted its holdings in Natera by 13.2% in the 1st quarter. Swiss National Bank now owns 47,900 shares of the medical research company’s stock worth $444,000 after acquiring an additional 5,600 shares during the period. Finally, Wells Fargo & Company MN boosted its holdings in Natera by 69.3% in the 4th quarter. Wells Fargo & Company MN now owns 51,644 shares of the medical research company’s stock worth $464,000 after acquiring an additional 21,140 shares during the period. Hedge funds and other institutional investors own 69.44% of the company’s stock.
Natera stock opened at $19.84 on Friday. The company has a market cap of $1.05 billion, a PE ratio of -8.28 and a beta of 2.00. The company has a debt-to-equity ratio of -18.90, a current ratio of 1.80 and a quick ratio of 1.68. Natera Inc has a 52 week low of $7.78 and a 52 week high of $20.00.
Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, May 8th. The medical research company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.01). The business had revenue of $62.34 million for the quarter, compared to analysts’ expectations of $54.86 million. Natera had a negative net margin of 58.84% and a negative return on equity of 752.93%. The business’s quarterly revenue was up 26.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.70) earnings per share. analysts forecast that Natera Inc will post -2.05 earnings per share for the current year.
A number of equities analysts have weighed in on the company. Piper Jaffray Companies restated an “overweight” rating and issued a $21.00 price target (up previously from $18.00) on shares of Natera in a report on Thursday. Robert W. Baird upped their price target on Natera from $17.00 to $20.00 and gave the stock an “outperform” rating in a report on Thursday, June 28th. Craig Hallum set a $23.00 price target on Natera and gave the stock a “positive” rating in a report on Thursday, June 28th. Morgan Stanley upped their price target on Natera from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Monday, June 25th. Finally, Canaccord Genuity upped their price target on Natera from $19.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, June 25th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Natera has an average rating of “Buy” and a consensus price target of $18.71.
In other news, CFO Michael Burkes Brophy sold 26,870 shares of the stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $18.29, for a total transaction of $491,452.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Claremont Creek Partners Fund sold 37,540 shares of the stock in a transaction that occurred on Monday, May 14th. The shares were sold at an average price of $11.48, for a total value of $430,959.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 178,364 shares of company stock valued at $2,801,816. Company insiders own 13.18% of the company’s stock.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera Inc (NASDAQ:NTRA).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.